

This card holds safety details for you and healthcare professionals regarding Lenalidomide Viatris and the Viatris Care program. Taking lenalidomide during pregnancy is expected to cause severe birth defects or death to an unborn baby. The Viatris Care program helps ensure that unborn babies are not exposed to lenalidomide.

A Prescription Authorisation Code (PAC) must accompany each prescription to confirm effective contraception is continually being used. If the patient is a woman of childbearing potential, pregnancy information is held in the Viatris Care program.

Pregnancy test dates and results are held on the Viatris Care program Database & each script must accompany a Prescription Authorisation Code (PAC).

LENALIDOMIDE VIATRIS (lenalidomide) 5 mg, 10 mg, 15 mg & 25 mg capsules. For multiple myeloma & myelodysplastic syndromes. Medicines have benefits and risks. If symptoms persist or you have side effects, see your healthcare professional. Take strictly as directed. View Consumer Medicine Information at www.medsafe.govt.nz for more information. Ask your doctor if this medicine is right for you. Special Authority & funding criteria may apply. Doctor's & pharmacy charges may apply. Viatris Limited, Auckland. LEN-2024-0004. TAPS DA2303MM-0213. Date of preparation: June 2024.

Lenalidomide

Viatris

(lenalidomide)

**Patient
Card**

Key Elements of Patient Card for Lenalidomide Viatrix

Patient name or initials: _____

Date of birth: _____

Doctor name: _____

Doctor address: _____

Doctor phone number: _____

Doctor to complete each section:

1. Indication (specify in detail according to Data Sheet):

2. Status of patient (tick one): program registration mandatory for all patients

Woman of non-childbearing potential

Woman of childbearing potential
(pregnancy testing is required)

Male

3. Counselling regarding the expected human teratogenicity of lenalidomide and the need to avoid pregnancy has been provided before first prescription.

Women of childbearing potential must:

- use effective contraception for at least 4 weeks prior to starting treatment, during treatment and treatment interruptions and for 4 weeks after stopping treatment
- have pregnancy tests every 4 weeks, or before each prescription if sooner than 4 weeks

Male patients with partners of childbearing potential, must use condoms during treatment and treatment interruptions and for at least 1 week after stopping treatment

Doctor's signature: _____ Date: _____